Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma has notified exchanges that its Board of Directors will meet on May 21, 2026 to consider and approve the audited financial results for Q4 and the full financial year ended March 31, 2026. The meeting is scheduled under SEBI Listing Regulations. The company has also extended its trading window closure from April 1, 2026 until May 23, 2026, with reopening on May 24, 2026. This is a routine pre-result announcement intimation and does not contain any financial details or forward-looking statements. The company will release the actual financial results after the board meeting for public disclosure.
This is a standard procedural filing that confirms the timeline for Q4 and FY2026 results announcement. No specific impact on the stock can be determined until actual numbers are disclosed. The extended trading window closure is a standard safeguard against insider trading ahead of material disclosures.